STOCK TITAN

Aridis Pharmaceuticals: Armistice reports 11.43%

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Neutral)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

Aridis Pharmaceuticals, Inc. (ARDS) common stock is the subject of a beneficial-ownership report by Armistice Capital, LLC and Steven Boyd. Each reports 5,096,251 shares, or 11.43% of the class, with shared voting and dispositive power and no sole power.

Armistice Capital is the investment manager of Armistice Capital Master Fund Ltd., the direct holder; Steven Boyd is Armistice Capital’s managing member and may be deemed to beneficially own the shares. The Master Fund disclaims beneficial ownership under the investment-management arrangement but has the right to receive dividends and sale proceeds.

Beneficially owned shares 5,096,251 shares Reported by each of Armistice Capital, LLC and Steven Boyd; shared voting and dispositive power.
Class ownership 11.43% Percentage reported by each reporting person.
beneficially own regulatory
"may be deemed to beneficially own the securities"
Beneficially own means having the economic rights and risks of a security—such as the right to receive dividends, sell the shares, or profit from price changes—whether or not your name appears on the official share register. Think of it like renting a car: you use it and reap the benefits even if the title lists someone else. Investors care because beneficial ownership determines who truly controls value, must be disclosed under securities rules, and can signal potential influence or trading activity that affects a stock’s price.
Investment Management Agreement regulatory
"pursuant to an Investment Management Agreement"
An investment management agreement is a written contract that hires a professional to make buying, selling and strategy decisions for an investment account or fund, and sets out their duties, fees, risk limits, performance measures and reporting requirements. It matters to investors because the agreement determines who controls the money, how much the service costs, what risks are allowed, and how success or failure is measured—think of it as the service contract that defines expectations and remedies for a hired portfolio manager.
shared voting power regulatory
"Shared voting power 5,096,251.00"
Shared voting power occurs when two or more parties jointly have the right to vote or decide how a block of company shares is cast, like co-owners who must agree before moving a piece of furniture. Investors care because who controls voting rights affects board elections, major corporate decisions and takeover outcomes, and shared control can alter regulatory disclosures and the practical influence any holder has over a company’s direction and value.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many ARDS shares do Armistice Capital and Steven Boyd report?

Armistice Capital, LLC and Steven Boyd each report 5,096,251 shares, equal to 11.43% of the class, with shared voting and dispositive power.

Who receives dividends or sale proceeds from the ARDS shares?

Armistice Capital Master Fund Ltd. is the direct holder and has the right to receive dividends or proceeds from a sale of the shares. Armistice Capital exercises voting and investment power under its Investment Management Agreement with the Master Fund.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google





040334104

(CUSIP Number)
09/30/2026

(Date of Event Which Requires Filing of this Statement)


Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)




schemaVersion:


SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



Armistice Capital, LLC
Signature:/s/ Steven Boyd
Name/Title:Steven Boyd - Managing Member
Date:11/16/2026
Steven Boyd
Signature:/s/ Steven Boyd
Name/Title:Steven Boyd
Date:11/16/2026
Exhibit Information

JOINT FILING STATEMENT PURSUANT TO RULE 13d-1(k) The undersigned acknowledge and agree that the foregoing statement on Schedule 13G, is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G, shall be filed on behalf of each of the undersigned without the necessity of filing additional joint acquisition statements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him or it contained therein, but shall not be responsible for the completeness and accuracy of the information concerning the others, except to the extent that he or it knows or has reason to believe that such information is inaccurate. Dated: November 16, 2026 Armistice Capital, LLC By: /s/ Steven Boyd Steven Boyd - Managing Member Steven Boyd By: /s/ Steven Boyd

Keep reading